~~<i id='A45C62850F'><strike id='A45C62850F'><tt id='A45C62850F'><pre id='A45C62850F'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

hotspot

author：knowledge 2025-09-29 19:05:21 - browse：591

Adam's take main illustration — Molly Ferguson/STAT

Shares of Apellis Pharmaceuticals are rebounding, driven by a growing belief among some investors that the serious safety issue that has derailed Syfovre, the company’s eye disease treatment, is receding.

Declaring the crisis over is premature, but that could change with more uneventful weeks. Apellis has been a takeout target before, and may be again, at an acquisition price nearly twice its current market value.

Apellis shares rose 32% last week, with most of the gains coming Friday on heavy trading volume. The reason: There have been no new cases of retinal occlusive vasculitis, or ROV, reported in people receiving injections of Syfovre.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Covid hospitalizations on the rise, Humana says

focus

Wikipedia

hotspot

knowledge

explore

focus

JeromeAdams,theU.S.surgeongeneralunderPresidentTrump,spokeThursdayattheSTATFutureSummit.STATTheTrump

WSS

Obesity drugs seen as possible treatment for liver disease MASH

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

6 phony surgeries that take placebo to the extreme

In utero gene editing: an explainer

How to protect patients from sexual assault

entertainment

hotspot

focus

Malaria cases in Florida and Texas: Here’s what you need to know

The (many) problems with a new study criticizing cancer screening

Hollywood unions extend contract negotiations for actors

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

Cancer drug shortages should be causing more outrage

Listen: Biogen's potential pivot, & Illumina's next chapter

Tori Bowie and the unacceptable rates of Black maternal death

Crinetics acromegaly drug succeeds in late

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

With competition flaring, obesity drug hits goal in liver disease study

Wikipedia

A solution to the after

Trump surgeon general acknowledges mistakes during Covid

Why Novartis is changing the name of its research labs

Dario to buy mental health app maker Twill in cash and stock deal

AstraZeneca chief proposes a novel edit to the drug pricing bill

Stem cell treatment guidelines are released by FDA

hotspot

knowledge

explore

focus